Literature DB >> 29523055

A case of refractory lupus nephritis complicated by psoriasis vulgaris that was controlled with secukinumab.

Y Satoh1, K Nakano1, H Yoshinari1, S Nakayamada1, S Iwata1, S Kubo1, I Miyagawa1, M Yoshikawa1, Y Miyazaki1, K Saito1, Y Tanaka1.   

Abstract

It has been reported that T helper 17 cells are involved in the pathogenesis of systemic lupus erythematosus, but there is no report on interleukin-17-targeted therapy. We report a case of a 62-year-old female who presented with psoriasis vulgaris and refractory lupus nephritis. Because her conditions were resistant to conventional treatment, and flow cytometry confirmed the proliferation of activated T helper 17 cells in peripheral blood, and examination of a renal biopsy tissue sample confirmed infiltration of numerous interleukin-17-positive lymphocytes to the renal interstitium, administration of the anti-interleukin-17A antibody secukinumab was initiated. After starting secukinumab the clinical and biological features were improved.

Entities:  

Keywords:  SLE; anti-IL-17 antibody; lupus nephritis; psoriasis vulgaris; secukinumab

Mesh:

Substances:

Year:  2018        PMID: 29523055     DOI: 10.1177/0961203318762598

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  9 in total

1.  Upregulated expression of STAT3/IL-17 in patients with systemic lupus erythematosus.

Authors:  Shih-Yao Chen; Ming-Fei Liu; Pin-Yu Kuo; Chrong-Reen Wang
Journal:  Clin Rheumatol       Date:  2019-02-15       Impact factor: 2.980

Review 2.  [Pathogenesis of systemic lupus erythematosus].

Authors:  S Finzel; S Schaffer; M Rizzi; R E Voll
Journal:  Z Rheumatol       Date:  2018-11       Impact factor: 1.372

Review 3.  IL-12 and IL-23/Th17 axis in systemic lupus erythematosus.

Authors:  Maddalena Larosa; Margherita Zen; Mariele Gatto; Diogo Jesus; Elisabetta Zanatta; Luca Iaccarino; Luis Inês; Andrea Doria
Journal:  Exp Biol Med (Maywood)       Date:  2019-01-21

Review 4.  Bite of the wolf: innate immune responses propagate autoimmunity in lupus.

Authors:  Sarthak Gupta; Mariana J Kaplan
Journal:  J Clin Invest       Date:  2021-02-01       Impact factor: 14.808

Review 5.  Current Insights and Future Prospects for Targeting IL-17 to Treat Patients With Systemic Lupus Erythematosus.

Authors:  Tomohiro Koga; Kunihiro Ichinose; Atsushi Kawakami; George C Tsokos
Journal:  Front Immunol       Date:  2021-02-01       Impact factor: 7.561

Review 6.  Current Evidence for IL-17/23 Blockade for the Treatment of Lupus Nephritis.

Authors:  Juan Camilo Santacruz; Sandra Pulido; Angelo Arzuaga; Marta Juliana Mantilla; Ana María Santos; John Londono
Journal:  Cureus       Date:  2021-12-01

7.  Analyzing the pathogenesis of systemic lupus erythematosus complicated by atherosclerosis using transcriptome data.

Authors:  Yimin Wang; Wenge Su; Yunlun Li; Jie Yuan; Minghao Yao; Xiaoyi Su; Yifei Wang
Journal:  Front Immunol       Date:  2022-07-22       Impact factor: 8.786

Review 8.  A Comprehensive Review of Biological Agents for Lupus: Beyond Single Target.

Authors:  Bingyi Yang; Ming Zhao; Haijing Wu; Qianjin Lu
Journal:  Front Immunol       Date:  2020-10-02       Impact factor: 7.561

9.  COVID-19 occurrence in one secukinumab-treated patient affected by hidradenitis suppurativa and systemic lupus erythematosus.

Authors:  Andrea Chiricozzi; Simone Garcovich; Dalma Malvaso; Giulia Giovanardi; Ketty Peris
Journal:  Int J Dermatol       Date:  2020-09-23       Impact factor: 3.204

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.